** India's Lupin LUPN.NS and Eris Lifesciences ERIS.NS rise about 2% each
** Macquarie says both pharmaceutical cos well-positioned to gain market share in India's insulin market after report suggests Novo Nordisk NOVOb.CO may discontinue some key brands in India
** Novo Nordisk is discontinuing India's largest selling insulin, Human Mixtard, among other older insulin brands in India, as per a Times of India report earlier this week
** LUPN on course for fifth consecutive session of gains, while ERIS rises for third day in a row
** Assuming the two companies capture Novo's vacated market share equally, it could mean ~10% revenue upside for ERIS and ~1% for LUPN - Macquarie
** Brokerage has "outperform" rating on LUPN and ERIS
** YTD, LUPN down 8.8%, while ERIS up 10.8%
(Reporting by Vivek Kumar M)
((VivekKumar.M@thomsonreuters.com;))